Clinical Trial Update: Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating a combination of a personalized mRNA-0217 vaccine with pembrolizumab in patients with advanced solid tumors and is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• mRNA-0217 vaccine (mRNA-0217 vaccine)

Snippet

Sponsor: Ruijin Hospital | Conditions: Advanced Solid Tumor | EARLY_Phase 1 | Status: RECRUITING